THC Effects on Glucose in Type 2 Diabetes

This study is looking at how THC (tetrahydrocannabinol), a component of cannabis, affects blood sugar (glucose metabolism) and blood vessel health (endothelial functioning) in people with Type 2 Diabetes. You would receive either inhaled THC or an inhaled placebo (an inactive substance) for two weeks, and then switch to the other for another two weeks after a break. Researchers will measure changes in how your body handles glucose and the health of your blood vessels to see if THC has an effect. The study aims to enroll up to 30 participants, but its current recruitment status is unclear.

Study design: This is a double-blind, placebo-controlled, cross-over study, meaning neither you nor the study team will know if you're receiving THC or placebo at any given time. Up to 30 participants will be randomized to receive either THC or placebo first, then switch after a break.
What's involved: You would have 10 study visits over approximately 16 weeks, including blood tests and tests to measure energy use and heart disease risks. You would also receive training on how to use the inhaled product.
Compensation: Not stated in the trial record.
Follow-up: The main measurements for the study are taken at 6 weeks after starting treatment, but the overall study duration is about 16 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

THC Effects on Glucose in Type 2 Diabetes

Recruiting

PHASE1Ages 21–70InterventionalBasic science

University of California, San Diego

~30 participants

Updated 2026-06-15 on ClinicalTrials.gov

What's tested:THCPlacebo

At a glance

Recruiting sites

1 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Change in Glucose Disposal Rate

Measured over 6 weeks

+1 more outcome measured

Conditions

Type 2 Diabetes

Where it's being run

1 sites across 1 states

California1

Who to contact

Todd May, MS

[email protected]

858-246-2169

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Males and Females 21-70 years old at the time of screening.

Females of non-child bearing potential must be ≥ 1 year post-menopausal or documented as being surgically sterile. Females of child bearing potential must agree to use two methods of contraception during the entire study.

Male subjects must be willing to use clinically acceptable method of contraception during the entire study.

Have a clinical diagnosis of Type 2 Diabetes on a stable medication regimen for at least 3 months.

BMI \> 25 kg/m2).

HbA1c \< 10%).

Negative urine toxicology result at screening visit.

Able to provide written informed consent approved by an Institutional Review Board (IRB).

Exclusion

History or presence of any clinically significant illness, as detected by history, physical examination, and/or laboratory tests, that might put the participant at increased risk of adverse events (e.g., history of psychotic disorder, clinically significant mood and/or anxiety disorder, liver, or renal disease).

No prior history of myocardial infarction, stroke or heart failure.

Whole blood donation of 1 pint (500 mL) within 8 weeks prior to Screening. Donations of plasma, packed RBCs, platelets or quantities less than 500 mL are allowed at investigator discretion.

Hemoglobin \< 9g/dL.

Liver enzymes ≥ 2 times upper normal limit and/or clinical signs/symptoms consistent with liver disease, including but not limited to nausea, vomiting, jaundice, itching, abdominal pain, or edema.

History of clinically significant adverse events associated with cannabis intoxication (e.g., severe anxiety and panic, paranoia and psychosis, sustained tachycardia, or severe hypotension).

History of seizures, head trauma, or other history of CNS insult that could predispose the participant to seizures.

Use of any THC containing products within 30 days prior to the screening visit.

Current use of tobacco products.

Individuals who are pregnant or lactating/breastfeeding.

Current use of insulin to treat Type 2 Diabetes.

Unable or unwilling to follow the study protocol or who are non-compliant with screening appointments or study visits.

Any other condition(s) that might reduce the chance of obtaining study data, or that might cause safety concerns, or that might compromise the ability to give truly informed consent.

What this trial measures

Change in Glucose Disposal Rate6 weeks
The change in glucose uptake from placebo treatment to THC treatment as measure by the hyperinsulinemic/euglycemic clamp.
Change in Vascular Endothelial Function6 weeks
The change in vascular endothelial function from placebo treatment to THC treatment as measured by reactive hyperemia-peripheral arterial tonometry (reactive hyperemia index).

Trialytics